Summary
Thermo Fisher Scientific Inc. reported solid revenue growth in the third quarter and first nine months of 2019, driven by strong performance across most of its segments, particularly Life Sciences Solutions and Analytical Instruments. The company successfully integrated key acquisitions, such as Brammer Bio, while also divesting its Anatomical Pathology business, demonstrating strategic portfolio management. Profitability saw a significant increase year-over-year, bolstered by higher sales and operational efficiencies, though partially offset by strategic growth investments and unfavorable foreign currency translation. The company maintained a strong liquidity position, with ample cash flow from operations and available borrowing capacity to meet its financial obligations. Financially, Thermo Fisher demonstrated revenue growth driven by organic demand and strategic acquisitions, while managing its cost structure effectively. The company reported a substantial increase in net income, benefiting from operational improvements and a favorable tax provision. Debt management was a key focus, with the company undertaking significant refinancing activities in early Q4 2019 to optimize its capital structure. Overall, Thermo Fisher's financial performance indicates a healthy, growing business with a clear strategy for expanding its market leadership in scientific instrumentation and services.
Financial Highlights
55 data points| Revenue | $6.27B |
| Gross Profit | $2.76B |
| R&D Expenses | $247.00M |
| SG&A Expenses | $1.54B |
| Operating Expenses | $5.33B |
| Operating Income | $946.00M |
| Interest Expense | $164.00M |
| Net Income | $760.00M |
| EPS (Basic) | $1.89 |
| EPS (Diluted) | $1.88 |
| Shares Outstanding (Basic) | 401.00M |
| Shares Outstanding (Diluted) | 404.00M |
Key Highlights
- 1Total revenues increased by 6% to $6.27 billion for the third quarter of 2019, and by 5% to $18.71 billion for the first nine months of 2019, compared to the prior year periods.
- 2Net income for the third quarter of 2019 rose to $760 million ($1.88 diluted EPS), a 7% increase from $709 million ($1.75 diluted EPS) in the prior year quarter.
- 3Life Sciences Solutions segment showed robust growth, with revenues up 13% in Q3 and 10% in the first nine months, driven by strong demand for bioproduction and biosciences products.
- 4The company completed the acquisition of Brammer Bio for approximately $1.7 billion and divested its Anatomical Pathology business for $1.13 billion, indicating active portfolio management.
- 5Operating income increased by 4% to $946 million in Q3 2019, with an operating margin of 15.1%, slightly down from 15.4% in Q3 2018, while for the nine-month period, operating income surged by 28% to $3.36 billion.
- 6Cash flow from operating activities was strong, totaling $3.06 billion for the first nine months of 2019, up from $2.74 billion in the prior year period, supporting investment and debt management.
- 7The company reported $6.76 billion in remaining performance obligations as of September 28, 2019, with approximately 70% expected to be recognized within the next twelve months.